Amani Therapeutics, Inc. — SEC Form D Filing

Amani Therapeutics, Inc. filed an SEC Form D on October 1, 2026, reporting $35.00M raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
October 1, 2026
Amount reported
$35.00M
Round stage
Series A
Industry
Pharmaceuticals
Website
https://amanitx.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Patients with treatment-resistant schizophrenia and schizoaffective disorder lack access to an effective treatment, clozapine, because its use is limited by severe safety concerns, specifically neutropenia, and burdensome blood-monitoring requirements.

Solution

Amani Therapeutics is developing AM-01, a fixed-dose combination product of clozapine and a Phase 3-ready NCE, to provide clozapine's efficacy while mitigating its safety liabilities like severe neutropenia and reducing monitoring requirements.

Verdict

This cleared because investors underwrote the de-risking of an established efficacy profile by addressing a known toxicity, not because the company was proving out a novel therapeutic mechanism. The implicit bet was on regulatory pathway efficiency and market share capture from a currently underutilized drug, assuming the safety improvements would translate directly into broader clinical adoption. Upside was limited by the reliance on incremental improvement to an existing molecule rather than the creation of entirely new therapeutic optionality.

Source: SEC EDGAR Form D filing